PATIENT'S NAME : MR.

SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 11:58 AM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

COMPLETE BLOOD COUNT

RBC PARAMETERS
HEMOGLOBIN (SLS Method) 15.7 gm/dl 13.0 - 18.0
R.B.C.COUNT(Electrical Impedence) 5.75 x10^6/ul 4.5 - 6.5
PCV (Electrical Impedence) 46.8 % 40 - 54
MCV (Electrical Impedence) 81.4 fL 75 - 95
MCH (Calculated) 27.3 pg. 26 - 32
MCHC (Calculated) 33.5 g/dl 32 - 36
RDW (Electrical Impedence) 13.2 % 11.0 - 14.5
Nucleated RBCs (Flow cytometry) 0.0 /100 WBCs Nil/100 WBCs
Mentzer Quotient (Calculated) 14.2 S/O
Remark <13:With Microcytic Anaemia-Rule out Beta Thalassemia
Trait
>13:With Microcytic Anaemia-Rule out Iron Deficiency
Anemia
WBC PARAMETERS (Flow Cytometry)
Total WBC Count 9200 /cumm 4000 - 11000
Neutrophils Low 44 % 53 - 68
Lymphocytes High 43 % 25 - 40
Monocytes 07 % 3-7
Eosinophils 06 % 0-6
Basophils 00 % 0-2
Immature Granulocytes 0.1 % 0 - 0.6
ABSOLUTE COUNTS (Calculated)
Neutrophils 4048 /cumm 2000 - 7500
Lymphocytes 3956 /cumm 1000 - 4000
Monocytes 644 /cumm 0 - 1000
Eosinophils High 552 /cumm 0 - 500
Basophils 0 /cumm 0 - 200
Immature Granulocytes) 9 /cumm 0 - 600
PLATELET PARAMETERS (Electrical Impedence)
Platelet Count 385 x10^3/uL 150 - 450
Mean Platlet Volume 8.9 fL 6 - 11
PDW (CV) Low 9.6 % 10.1 - 16.1
PCT High 0.34 % 0.17 - 0.32
Morphology-Smear Normochromic Normocytic
Method:Fully Automated 5 part Cell counter Sysmex XN 1000/Sysmex XN550 using EDTA whole blood.
Note:Change in reference ranges (w.e.f.19/04/2022).Normal ranges vary with age and sex.
Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 1 of 14

DR.SHAZIA KHAN, M.B.B.S. (DPB)

MC- 3335
Reg. No.: 2008/02/0380
 PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:50 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

* RENAL FUNCTION TEST

Total Protein,serum 6.93 g/dl 6.4 - 8.3
Method: Biuret,end point (Photometry).

Albumin,serum 4.33 g/dl 3.5 - 5.0

Method:Bromocresol Green (BCG,Photometry)

Globulin (Calculation) 2.60 g/dl 1.8 - 3.6

A/G Ratio (Calculation) 1.67 1.2 - 2.5
Blood Urea Nitrogen,Serum 12.50 mg/dl 6.0 - 20.0
Method: Urease,UV (Photometry).

Creatinine, Serum 0.81 mg/dl 0.72 - 1.25

Method: Alkaline picrate-kinetic (Photometry).

Uric Acid,Serum 5.7 mg/dl 3.7 - 7.7

Method: Uricase (Photometry)

Calcium,serum 9.1 mg/dl 8.4 - 10.2

Method : Arsenaso III (Photometry).

Inorganic Phosphorus,Serum High 5.30 mg/dl 2.5 - 4.5

Method: Phosphomolybdate (Photometry).

Sodium,serum 139 mEq/l 136 - 145

Method: ISE indirect (Potentiometry).

Potassium,serum 4.43 mEq/l 3.5 - 5.1

Method: ISE indirect (Potentiometry).

Chloride,serum 104 mEq/L 98 - 107

Method: ISE Indirect (Potentiometry)

Blood Glucose Fasting,Plasma 83 mg/dl 70 - 99 Normal FPG

100-125 Impaired FPG
FPG >= 126 Diabetes Mellitus
Method : Hexokinase / G-6-PDH
Note :Reference ranges vary with method/analyser used for a particular test.

..........END OF REPORT.......... Page 2 of 14

* NOT IN THE NABL SCOPE

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 11:21 AM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

PROTHROMBIN TIME
Prothrombin Time - Test 12.6 seconds 12.1 - 15.5

Mean Normal Prothrombin Time 13.8 seconds

(MNPT)

Prothrombin Index 109.52 %

Prothrombin Ratio 0.91

I.S.I. Value 1.07

International Normalised Ratio 0.91 Less than 1.2

Therapeutic Range Of INR - 2-3

Method : Fully Automated Coagulometer(STAGO SATELLITE MAX). using citrate plasma sample.
Note :
*Change in Prothrombin Time reference ranges are as per the MNPT derived values.
*Change in INR normal range (w.e.f.29/03/2025)

INTERPRETATION:
Prothrombin Time helps in the detection and diagnosis of a bleeding disorder or an excessive clotting disorder.
It is used as a screening test to assess the coagulation activity of the Extrinsic and the common coagulation pathway and may be prolonged
due to deficiencies of Factor I,II,V,VII or X, due to a liver disease, Vitamin K deficiency or due to presence of inhibitors.
The test is also used to monitor effects of anti coagulant therapy (Heparin, Warfarin etc)
The INR is preferred for patients stabilized on oral anti coagulant therapy, as it reduces the inter method variability.
An INR < 2 reflects insufficient anticoagulation, and a marked elevation of INR > 3 in patients on oral anti coagulants is a marker of
excessive anticoagulation and requires prompt action.

LIMITATIONS:
•The Prothrombin Time (PT) may not be sensitive to mild deficiencies of single clotting factors and is usually prolonged if the plasma levels
of any of the requisite factors is below 10 % of the normal.
•The PT is more sensitive to deficiencies of Factor VII and X than to deficiencies of factor I and II, and is not sensitive to abnormalities in
factors involved in the intrinsic coagulation pathway ( factors VIII, IX,XI and XII) or in Protein C or S deficiencies.
•The Prothrombin Time (PT) is less sensitive to the anticoagulant action of Heparin than is the APTT.
•An Excessive intake of a diet rich in Green leafy vegetables (Spinach, Broccoli), increases the body’s absorption of Vitamin K and could
interfere with the anti coagulant mechanism.
•Alcoholism or excessive alcohol ingestion prolongs PT levels.
•Diarrhea and vomiting may decrease PT levels due to dehydration.
•Various drugs, including over the counter medications (Aspirin, laxative products, acetaminophen etc), also alter the effects of
anticoagulants and PT value.

Note : Laboratory Test Results should always be considered in the context of clinical observations in making a final Diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 3 of 14

Dr.Dhaval V.Sangoi, (MD,DPB)

MC- 3335
Reg.No.:2005/04/2361
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 11:39 AM

Andheri (West) REPORT DATE : 17/06/2025 1:11 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

BLOOD GLUCOSE POST PRANDIAL

Blood Glucose (Post Prandial),Plasma 101 mg/dl 70 - 139 :Normal 2 hrs Plasma
Glucose
140 - 199:Impaired Glucose Tolerance
Method : Hexokinase / G-6-PDH
Note: Change in reference range (w.e.f.20/05/19)

Interpretation:

As Per the ADA (American Diabetes Association) criteria, diagnosis of Diabetes Mellitus is based on any one/more of the following:

* Fasting Plasma Glucose (FPG) > 126 mg/dl on more than one occasion.
* Symptoms of Diabetes Mellitus (Polydipsia, Polyuria, Unexplained weight loss, Polyphagia etc ) and a Random Plasma Glucose > 200 mg/dl.
* Two Hour Plasma Glucose >/= 200 mg/dl.
* Glycosylated Hemoglobin A1c (HbA1c) >/= 6.5 %

Note: Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 4 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:50 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Bio. Ref. Int

CREATININE WITH ESTIMATED GLOMELULAR FILTRATION RATE (EGFR)

Creatinine, Serum 0.81 mg/dl 0.72 - 1.25
Method: Alkaline picrate-kinetic (Photometry).

Estimated Glomelular Filtration Rate More than 90.0 ml/min/1.73m^2

(eGFR)
Note:Change in normal ranges & calculation method (w.e.f 1/4/2019)

Interpretation:

*The test is indicated in the diagnosis of renal insufficiency, adjusting the dosage of renally excreted medications, and monitoring renal
transplant patients.

*An estimated GFR (e-GFR) is calculated from serum Creatinine using an isotope dilution mass spectrometry (IDMS) traceable equation (MDRD
Equation) for ages 18 and above, as an effective way to help detect CKD and those with risk factors for CKD (DM, Hypertension, cardiovascular
disease or family history of kidney disease).

GFR categories as per the KDIGO (Kidney Disease: Improving Global outcome) Guidelines are as follows:
====================================================================
STAGE DESCRIPTION GFR (ml/min /1.73m2)
====================================================================
G1 Normal or High >/= 90
--------------------------------------------------------------------
G2 Mildly Decreased 60 - 89
--------------------------------------------------------------------
G3a Mildly to Moderately Decreased 45 - 59
--------------------------------------------------------------------
G3b Moderately to severely decreased 30 - 44
--------------------------------------------------------------------
G4 Severely Decreased 15 - 29
--------------------------------------------------------------------
G5 Kidney Failure < 15
====================================================================
* In the absence of evidence of Kidney Damage, Neither GFR category G1 nor G2 fulfill the criteria for CKD.

Limitations:

*The MDRD Equation does not require weight and height variables because the results are reported normalized to the accepted average adult
surface area. The MDRD study Equation can therefore be applied to determine level of kidney function, regardless of a patient’s size. (Consult
a nephrologist if a patient has unusual physical considerations).
*Creatinine based estimating equations should be used only for patients with stable Creatinine concentrations.
*Creatinine –based estimating equations may not be suitable for all populations and are not recommended for use with
- Individuals with unstable creatinine concentrations (pregnant woman, patients with serious co-morbid conditions and hospitalized
patients).
- Patients of extreme body size or muscle mass (e.g obese, severely malnourished, paraplegics or in other muscle wasting diseases or a
neuromuscular disorder) or in patients with unusual dietary intake vegetarian, creatine supplements etc).

[Application of the equation to the above patient groups may lead to errors in the GFR estimation.
Thus, Confirmatory tests with exogenous measured GFR or measured Creatinine Clearance should be performed for such people, in whom estimates
based on serum/plasma/ blood creatinine alone may be Inaccurate].
*Interferences have been reported with marked increase in serum Bilirubin.
*Methodological interferences have also been observed with ascorbic acid, L-dopa etc.

Note: The reported e-GFR is the best estimate of a patient’s GFR; It is not the patients actual GFR.

..........END OF REPORT.......... Page 5 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:50 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

LIPID PROFILE
Total Cholesterol 153 mg/dl Less than 200
HDL Cholesterol 47 mg/dl 40 - 60
Cholesterol/HDL Ratio 3.3 2-5
Triglyceride 97 mg/dl Less than 150
LDL Cholesterol 87 mg/dl Less than 100
VLDL Cholesterol 19 mg/dl 0 - 35
LDL / HDL Ratio 1.8 0 - 3.5

Method: Photometry using serum sample.

INTERPRETATION :
Following are the results interpretation as per the recommendations of The Adult Treatment Panel III of the national cholesterol education
program for coronary risk analysis :
==========================
TOTAL CHOLESTEROL LEVEL
==========================
< 200 mg/dl : Desirable[Low Risk of Coronary Heart Disease]
200 – 239 mg/dl : Borderline High[Cholesterol level = 200 mg/dl raises the risk of CHD]
>/= 240 mg/dl : High [Person has more than twice the risk of developing CHD]

*The Cholesterol/HDL ratio provides more information than either values alone. The higher the Cholesterol/HDL ratio,the greater the risk for
developing atherosclerosis.

---------------------- -------------------- --------------------

HDL Cholesterol TRIGLYCERIDES LEVEL LDL CHOLESTEROL
---------------------- -------------------- --------------------
40 - 60 mg/dl : Normal < 150 : Normal < 100 mg/dl : Optimal
> 60 mg/dl : Considered Protective against CHD 150 - 199 : Borderline High 100 - 129 mg/dl : Above Optimal
< 40 mg/dl : Major risk factor for CHD >200 : High 130 - 159 mg/dl : Borderline High
160 - 189 mg/dl : High
> 190 mg/dl : Very High

Limitations: * Test results may show interferences due to pregnancy, certain drugs such as estrogens and other drugs (such as androgenic and
related steroids),and insulin therapy etc.
* Values may be increased in acute illness, colds or flu.Obesity, Stress, physical inactivity, cigarette smoking and alcohol consumption may
lead to increased test values.
* Intraindividual variations, seasonal as well as positional variations have been observed.
Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 6 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:50 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

LIVER FUNCTION TEST

Total Protein,serum 6.93 g/dl 6.4 - 8.3
Method: Biuret,end point (Photometry).

Albumin,serum 4.33 g/dl 3.5 - 5.0

Method:Bromocresol Green (BCG,Photometry)

Globulin (Calculation) 2.60 g/dl 1.8 - 3.6

A/G Ratio (Calculation) 1.67 1.2 - 2.5

Total Bilirubin,serum 0.50 mg/dl 0.2 - 1.2

Direct Bilirubin,serum 0.27 mg/dl 0 - 0.5

Indirect Bilirubin (Calculation) 0.23 mg/dl 0 - 0.9

SGOT,serum 24 U/L 5 - 34
Method: UV without P5P (Photometry)

SGPT,serum 40 U/L 0 - 55
Method: UV without P5P (Photometry).

Alkaline Phosphatase,Serum 69 U/L 40 - 150

Method : PNPP,AMP Buffer (Photometry).

GGT,Serum 33 U/L 12 - 64

Method: G-glutamyl-carboxy-nitroanilide (Photometry).

Interpretation:
Liver function tests are a group of tests performed to help diagnose or monitor liver diseases by measuring the levels of proteins, liver
enzymes and bilirubin. The test may also be performed as part of a regular checkup to screen patients who are at risk of liver disease or to
monitor the progress of disease and response to drugs or other treatments.

Note :
*Reference ranges vary with method/analyser used for a particular test.
*Laboratory Test Results should always be considered in the context of clinical observations in making a final Diagnosis and Patient management
decisions.

..........END OF REPORT.......... Page 7 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:35 PM

PRINT DATE : 17/06/2025 2:36 PM

IMMUNOLOGY

Investigation Status Result Unit Bio. Ref. Int

INSULIN (FASTING)
Insulin Fasting,Serum 17.40 µU/ml 2 - 25
Method: CMIA

Interpretation :

*The primary clinical application of insulin measurement is in the evaluation of patients with fasting hypoglycemia and in the diagnosis of
insulinoma. Also helpful in evaluating insulin resistance and insulin secretion, and in selecting the optimal management therapy for patients
with type 2 diabetes mellitus.

Limitations :

* Measuring insulin along with OGTT, as an aid to early diagnosis of diabetes mellitus, is an approach which is not recommended.
* A single random blood sample may provide insufficient information due to wide variations in the time responses of insulin and blood glucose
which are found among individuals and various clinical conditions.
* To differentiate between insulinoma and factitious hypoglycemia, ratio of insulin to blood glucose or a insulin to C-peptide ratio may be
more valuable than insulin alone.
* Antibodies to insulin develop in almost all diabetics treated with exogenous insulin and monitoring of insulin may be of significance in the
treatment of such patients.
* Depressed levels of insulin are generally seen in type 1 Diabetes mellitus and hypopituitarism.
* Individuals who are obese have somewhat higher fasting insulin levels than adults with a normal weight.
* Patients on oral contraceptives may have increased levels of fasting insulin.

Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

INSULIN (POST PRANDIAL)

Insulin Post Prandial (2Hrs.),Serum 61.30 µUml 2hrs Post Glucose:16-166
Method: CMIA

Note: Change in reference range (w.e.f.28/05/2019)

Interpretation :

*The primary clinical application of insulin measurement is in the evaluation of patients with fasting hypoglycemia and in the diagnosis of
insulinoma. Also helpful in evaluating insulin resistance and insulin secretion, and in selecting the optimal management therapy for patients
with type 2 diabetes mellitus.

Limitations :

* Measuring insulin along with OGTT, as an aid to early diagnosis of diabetes mellitus, is an approach which is not recommended.
* A single random blood sample may provide insufficient information due to wide variations in the time responses of insulin and blood glucose
which are found among individuals and various clinical conditions.
* To differentiate between insulinoma and factitious hypoglycemia, ratio of insulin to blood glucose or a insulin to C-peptide ratio may be
more valuable than insulin alone.
* Antibodies to insulin develop in almost all diabetics treated with exogenous insulin and monitoring of insulin may be of significance in the
treatment of such patients.
* Depressed levels of insulin are generally seen in type 1 Diabetes mellitus and hypopituitarism.
* Individuals who are obese have somewhat higher fasting insulin levels than adults with a normal weight.
* Patients on oral contraceptives may have increased levels of fasting insulin.

Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 8 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:35 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

THYROID PANEL
Free T3, Serum 2.35 pg/ml 1.71 - 3.71

Free T4, Serum 0.96 ng/dl 0.7 - 1.48

Thyroid Stimulating Hormone 3.163 uIU/ml 0.50 - 8.9

(TSH),(Ultrasensitive), Serum

Method:CMIA

Interpretation: The Age Specific Reference Ranges is as given below:

-----------------------------------------------------------------------------------------------
AGE FreeT3(pg/ml) AGE FreeT4(ng/dl)
-----------------------------------------------------------------------------------------------
4 days - < 1 yr 2.34 – 4.87 1 – 4 days(Newborns) 2.2 – 5.3
1 yr - < 12 yrs 2.79 – 4.42 5 days – 15 days 1.1 – 3.2
12 yrs - < 15 yrs(Females) 2.47 – 3.96 15 days - < 30 days 0.7 – 2.5
12 yrs – 15 yrs (Males) 2.86 – 4.35 30 days - < 1 yr 0.9 – 1.7
15 yrs - < 19 yrs(Females) 2.34 – 3.70 1 yr - < 19 yrs 0.9 – 1.4
15 yrs - < 19 yrs(Males) 2.27 – 3.83 21yrs – 87 yrs (Adults) 0.7 – 1.48
----------------------------------------------------------------------------------------------
Adult 1.71 – 3.71 Pregnancy(1st Trimester) 0.7 – 2.0
Pregnancy 2.00 – 3.80 Pregnancy(2nd & 3rd Trimester) 0.5 – 1.6
----------------------------------------------------------------------------------------------
AGE TSH(µIU/ml)
-------------------------------------------------------
Premature (28 – 36 wks) 0.7 – 27.0
1 day - 4 days 1.0 – 39.0
5 days - 20 weeks 1.7 – 9.1
21 weeks - 20 years 0.7 – 6.4
Adults : 21 yrs - 54 years 0.49 – 4.67
Adults : >55 years 0.5 – 8.90
Pregnancy (1st Trim) 0.1 – 2.5
Pregnancy (2nd Trim) 0.2 – 3.0
Pregnancy (3rd Trim) 0.3 – 3.0
-------------------------------------------------------
* Elevated TSH levels and Low FT4 indicates Primary Hypothyroidism (Due to Thyroid Disease).
* A Low/Normal TSH and a Low FT4 generally suggests Secondary Hypothyroidism.
* A Low TSH and High FT4 indicates Hyperthyroidism.
* As per the guidelines issued by the American Association of Clinical Endocrinologists (AACE),TSH levels between 4.7 – 10 µIU/mL is considered
subclinical Hypothyroidism.
* Values < 0.1 mIU/mL are an indication of overt Hyperthyroidism or Exogenous Thyrotoxicosis.
* The major clinical need for FT3 measurements is for the identification of patients with T3 Thyrotoxicosis (a variant of Hyperthyroidism) who
have suppressed TSH levels with normal T4 and FT4 concentrations but increased T3 concentrations. Measurement of FT3 concentrations is also
useful to identify patients with Subclinical Hyperthyroidism who have Low TSH and Normal FT4 and FT3 concentrations.
Limitations:
* TSH may not be useful to evaluate thyroid status of hospitalized patients with acute medical or psychiatric illness.
* Pregnancy may result in an increase or decrease in test values.
* Various drugs may interfere with test results. Heparin causes falsely elevated FT4 values and Anticonvulsant therapy (particularly Phenytoin)
may result in decreased FT4 values.
* Rheumatoid factor and Heterophilic antibodies may result in falsely increased or decreased test values.
* TSH levels may vary diurnally by upto 50% and upto 40% variations on specimens performed serially during the same time of the day.
* In circumstances where the patient fails to provide the age, the default reference range provided will be that of the adult. (As Reference
ranges are Age Dependent).

Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 9 of 14

Dr.Dhaval V.Sangoi, (MD,DPB)

MC- 3335
Reg.No.:2005/04/2361
 PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:35 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

* HIGH SENSITIVE CRP

HsCRP-High Sensitivity CRP,Serum 1.68 mg/L < = 5.0

Note : Change in Reference range (w.e.f. 09/06/2025)

Method : Immunoturbidometric.
Interpretation :

1. High sensitivity C reactive protein (hs CRP)measurements may be used as an

independent risk marker for the identification of individuals at risk for
future cardiovascular disease.
2. hs CRP when used in conjunction with traditional risk factors may be useful
as an independent marker for prognosis of recurrent events in patients with
stable coronary disease or acute coronary syndromes.
3. Patients with evidence of active infection, systemic inflammatory processes
or trauma should not be tested for cardiovascular risk assessment until these
conditions are abated.

..........END OF REPORT.......... Page 10 of 14

* NOT IN THE NABL SCOPE

Dr.Dhaval V.Sangoi, (MD,DPB)

MC- 3335
Reg.No.:2005/04/2361
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:35 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

VITAMIN B12
Vitamin B12,Serum 238.00 pg/ml WHO CRITERIA FOR VITAMIN B12
INTERPRETATION:
< 150 : Deficient
150 - 200 : High risk of Vitamin B12
deficiency
> 201:Unlikely to be deficient
Method: CMIA

Interpretation:

* Vitamin B 12 is mainly used in the investigation of Macrocytic anemia and in the workup of deficiencies seen in Megaloblastic anemias.
* Vitamin B12 also assists in the diagnosis of CNS disorders and evaluation of malabsorption syndromes.
* As low concentrations of Holotranscobalamin (Active B12) occur before low concentrations of Total serum B12, preceding the stage of B12
deficiency or the stage of hematological or irreversible neurological damage; Active B12 is considered a more reliable marker of impaired B12
status than a low concentration of Serum Vitamin B12 and should be considered as a first line laboratory parameter to screen for Vitamin B12
deficiency.

Limitations :

* Vitamin B12 concentrations within the reference intervals may not necessarily reflect adequate vitamin B12 status. Conversely, low serum
vitamin B12 concentrations may not be indicative of vitamin B12 deficiency as low serum B12 concentrations may be due to reduction in
Haptocorrin.
* Since measurement of Total Vitamin B12, has limitations of sensitivity and specificity, Vitamin B12 bound to transcobalamin (holoTC) has been
proposed as a potentially more useful alternative indicator of Vitamin B12 status. Measurement of both holoTC (Active vitamin B12) and Total
Vitamin B12 however, provides a better screen for Vitamin B12 deficiency than either assay alone.
* If clinical symptoms suggest deficiency, measurement of Active- B12 and testing of other metabolic markers (Folic acid, Intrinsic factor
blocking antibodies, MMA and Homocystein) should be considered, even if B12 concentrations are normal.
* Renal insufficiency constitutes a common and important exceptional condition for the interpretation of cobalamine markers.
* Alcohol, pregnancy, smoking and drugs such as anticonvulsants, ascorbic acid, metformin, oral contraceptives etc may decrease vitamin B12
levels.
* Patients taking Vitamin B12 supplementation may have misleading results.
* Methylmalonic acid and Homocystein are increased in vitamin B12 deficiency and are generally considered more sensitive indicators of Vitamin
B12 status.
* Active Vitamin B12, like total serum B12, varies to a limited extent by age, gender or race.
* Active B12 levels reflect vitamin B12 status independent of recent absorption.

Note:Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient
management decisions.

..........END OF REPORT.......... Page 11 of 14

Dr.Dhaval V.Sangoi, (MD,DPB)

MC- 3335
Reg.No.:2005/04/2361
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:38 AM

Andheri (West) REPORT DATE : 17/06/2025 12:29 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Bio. Ref. Int

URINE EXAMINATION TEST REPORT

PHYSICAL EXAMINATION
Color Pale yellow Pale Yellow / Yellow
Appearance Slightly hazy
Deposit Absent Absent
Chemical Examination (Automated Dipstick Method)
Specific Gravity (Refractometry) 1.025 1.003 - 1.030
Reaction/pH (Indicator Based) Acidic (5.0) 4.5 - 7.5
Leucocytes (Estrase Activity) Negative Negative
Nitrite (Greiss Method) Negative Negative
Blood (Peroxidase Like Action of HGB) Negative Negative
Protein (Protein Error of PH indicator) Negative Negative
Glucose (Enzymatic) Negative Negative
Ketone (Alkali Na-nitroprusside) Negative Negative
Bilirubin (Azo Coupling) Negative Negative
Urobillinogen (Azo Coupling) Normal Normal
MICROSCOPIC EXAMINATIONA (DIGITAL IMAGING ANALYSIS)
WBC (Pus Cells) 2-4/hpf 0 - 5/HPF
RBC Absent 0 - 2/HPF
Epithelial Cells Occasional 0 - 8/HPF
Cast Absent < 1.0 /LPF
Crystals Calcium oxalate present Absent
Bacteria Absent
Yeast Like Cells Absent Absent
Other Findings Nil

Note: Change in reference range & method (w.e.f.24/11/2021)

Method : Refractometry & Digital Imaging Analysis done on Fully Automated Beckman Iris Analyser.

Note :
* Urine routine and microscopy is a screening test.
* Pre-test conditions & improper sample collection container if not observed may interfere with test results (e.g.mid-stream urine,collected in
a clean,dry,sterile container is recommended for routine urine analysis,avoid contamination with any discharge from vaginal urethra,perineum,as
applicable,avoid prolonged transit time & undue exposure to sunlight).
* Negative nitrite test does not exclude the presence of bacteria or urinary tract infections.
* Trace Proteinuria can be seen with many physiological conditions like prolonged recumbency,exercise,high protein diet etc.
* False reactions for bile pigments,proteins,glucose and nitrites can be caused by peroxidase like activity by disinfectants,therapeutic
dyes,ascorbic acid and certain drugs etc.
* Physiological variations may affect the test results.
The reference ranges may vary widely between individual laboratories and between different assay methods.

..........END OF REPORT.......... Page 12 of 14

Dr.Dhaval V.Sangoi, (MD,DPB)

MC- 3335
Reg.No.:2005/04/2361
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 12:51 PM

PRINT DATE : 17/06/2025 2:36 PM

IMMUNOLOGY SPECIAL

Investigation Status Result Unit Bio. Ref. Int

VITAMIN D (25-HYDROXY)
VITAMIN D,Serum 35.4 ng/ml 30 - 50
Method :CMIA

Interpretation:

*Vitamin D (25 –OH vitamin D) is generally accepted as the best indicator of an individual’s Vitamin D status and is mainly indicated in the
diagnosis of Vitamin D deficiency, differential diagnosis of causes of rickets and Osteomalacia, monitoring Vitamin D replacement therapy and
in the diagnosis of Hypervitaminosis D.
-------------------------------------------------
Vitamin D Status Reference Range(ng/ml)
--------------------------------------------------
Deficient : < 10
Insufficient : 10 - 30
Sufficient : 30 - 50
At risk of adverse effects : > 50
Toxicity : > 100
--------------------------------------------

Guidelines from the Endocrine Society and the UK osteoporosis society recommends that , routine screening for Vitamin D deficiency is
warranted in those with risk of deficiency and not on a population basis.

[Candidates for screening are listed as patients with rickets, Osteomalacia,Osteoporosis,CKD,hepatic failure,malabsorption
syndromes,hyperparathyroidism,granuloma forming disorders, pregnant and lactating woman,older adults with history of falls or with history of
non traumatic fractures,obese,patients with some lymphomas and patients on medications such as anticonvulsants, glucocorticoids, AIDS
medication and antifungal.]

Limitations:

* Given the absence of assay standardization and lack of consensus regarding clinical cut off values, Vitamin D levels must be interpreted
within the clinical context of each patient and one should not rely solely on cut off values based on so called normal values.
* Circulatory concentrations of 25 (OH) Vitamin D are increased by exposure to sunlight and may show seasonal variation with the highest
concentrations in summer and lowest concentrations in winter and spring.
* Concentrations of Vitamin D are influenced by latitude, sunscreen use and skin pigmentation. Concentrations = 100 ng/ml may be detected in
individuals with extensive sun exposure.
* Concentrations vary depending on ethnic background, age,pregnancy and increasing supplementation with Vitamin D.

Note: The Accuracy of measurement varies widely between individual laboratories and between different assay methods.
Laboratory Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient management
decisions.

..........END OF REPORT.......... Page 13 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380
PATIENT'S NAME : MR. SIDDHANT SHARMA AGE / SEX : 29 Years / M

ID No : 2536803 REG.DATE/TIME : 17/06/2025 9:26 AM

REF. BY Dr. : Girish M.Parmar. SAMPLE COLL.TIME : 17/06/2025 9:44 AM

Andheri (West) REPORT DATE : 17/06/2025 1:48 PM

PRINT DATE : 17/06/2025 2:36 PM

Investigation Status Result Unit Bio. Ref. Int

HBA1C (GLYCOSYLATED HEMOGLOBIN A1C)

HbA1c Level, Blood 5.4 % < 5.7 % - Normal
5.7 - 6.4 % - Increased risk for
Diabetes (Pre Diabetes)
> 6.5 % - Diabetic range
Mean Plasma Glucose 114.9 mg/dl
(Average Glucose Level For The Last 3 Months)
Method : Ion Exchange High Performance Liquid Chromatography (HPLC) / Enzymatic method using EDTA Whole Blood sample.

Interpretation:
* HbA1c test is the estimated average blood glucose levels during the previous 2-3 months.
* The HbA1c test is used to aid in the possible diagnosis of Diabetes mellitus, in screening for Pre diabetes and to identify patients who may
be at risk of developing diabetes, as an index of diabetic control and monitoring compliance and long term blood glucose level control in
patients with diabetes. Also useful in predicting development and progression of diabetic microvascular complications.
* HbA1c levels < 7% has been shown to reduce microvascular and neuropathic complications of Type 1 and Type 2 Diabetes.
As Per the ADA (American Diabetes Association) criteria, diagnosis of Diabetes Mellitus is based on any one/more of the following:
*Fasting Plasma Glucose (FPG) = 126 mg/dl on more than one occasion.
*Symptoms of Diabetes Mellitus (Polydipsia,Polyuria,Unexplained weightloss,Polyphagia etc) and a Random Plasma Glucose >=200 mg/dl.
*Two Hour Plasma Glucose >= 200 mg/dl.
*Glycosylated Hemoglobin A1c (HbA1c) = 6.5 %

Limitations:
*When using HbA1c to diagnose Diabetes, it is important to recognize that A1c is an indirect measure of average blood Glucose levels and other
factors that may impact hemoglobin glycation independently of glycemia should be taken into consideration, including age, race / ethnicity and
anemia (iron deficiency anemia, hemolytic anemia) / hemoglobinopathies.
*Hemoglobin variants or HbA2 > 5% and HbF > 20 % can interfere with the measurement of A1c, and needs to be correlated with Abnormal Hb
studies and further workup.
*Marked discrepancies between measured A1C and plasma glucose levels should prompt consideration that the A1c assay is not reliable for that
individual.
*The HbA1c assay should not be used to diagnose or monitor diabetes in conditions associated with increased red blood cell turnover (e.g sickle
cell disease), pregnancy, hemodialysis, recent blood loss or transfusion or erythropoietin therapy, and only plasma blood glucose criteria to
diagnose diabetes should be used.
*Unless there is a clear clinical diagnosis, (e.g patient in a hyperglycemic crisis or with classic symptoms of hyperglycemia and a random
blood glucose =200mg/dl), a second test is required, for confirmation of a test result which is above the diagnostic threshold.
*Certain medications, such as Glucocorticoids, Thiazide diuretics, and Atypical antipsychotics are known to increase the risk of diabetes and
should be considered when deciding whether to screen.
*This method is certified by the National Glycohemoglobin Standardization Program (NGSP), Standardized to International Federation of clinical
Chemistry and Laboratory Medicine (IFCC), and traceable to DCCT.
*HbA1c values may vary with different methodologies or even between different laboratories using the same methodology.
Note: Test Results should always be considered in the context of clinical observations in making a final diagnosis and Patient management
decisions.

..........END OF REPORT.......... Page 14 of 14

DR.SHAZIA KHAN (M.B.B.S.,DPB)

MC- 3335
Reg. No.: 2008/02/0380